Warner Chilcott tosses shareholders $1bn and pulls down the for sale sign
This article was originally published in Scrip
Talks with potential buyers for the Irish speciality pharma company Warner Chilcott have ended without result, the Nasdaq-listed company has announced. Instead, it plans to return cash to shareholders in the form of a $4.00 per share special cash dividend and a share buyback. In April, Warner Chilcott said it was conducting a strategic review of a "broad range of alternatives to enhance shareholder value, including preliminary discussions with potential offerors", after rumours suggested that Bayer may be preparing a $32 per share bid.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.